NO. 81770491 Wu (PI) 01/01/18-12/31/21 National Natural Science Foundation of China CIRP-TLR4 interaction in endothelial hyperpermeability during trauma and shock The objective of this project is to define the role and molecular mechanisms of extracellular CIRP-induced microvascular hyperpermeability under trauma-relevant inflammatory conditions.
7R21 NS072608 Wu (PI) 05/01/11-04/30/15 NIH/NINDS ($456,500) Ghrelin and Traumatic Brain Injury The proposed studies will 1) define the contribution of ghrelin downregulation on brain injury after TBI, and 2) determine the mechanism responsible for ghrelin’s beneficial effects after TBI.
R44DK075149 Wu (PI) 08/01/10-07/31/13 NIH/NHLBI ($1,504,443) A New Therapy for Bowel Ischemia-Reperfusion Injury The purpose of this SBIR Phase II proposal is to further develop human AM/AMBP-1 as a novel treatment for patients with intestinal ischemia/reperfusion (I/R) injury.
R44HL091602 Wu (PI) 09/23/08-08/31/12 NIH/NHLBI ($2,029,091) A Novel Therapy for Septic Shock This SBIR Phase I/Phase II Fast-Track proposal is intended to develop rhMFG-E8 as a novel therapy for patients with sepsis and septic shock.
HHSN27520120002C Chaung (PI) 11/08/11-08/07/12 NIH/NIAAA MFG-E8 for alcohol-induced tissue injury and infections The primary objective of this SBIR Program Contract is targeted toward demonstrating the feasibility of further development and commercialization of rhMFG-E8 as a novel therapeutic agent in reducing alcohol/sepsis-induced tissue damage and mortality. Role: Co-PI R44GM073249 Wu (PI) 06/01/05-06/30/11 NIH/NIGMS ($1,448,416) Treatment of Surgical Sepsis with AM/AMBP-1 The goal of this proposal is to provide sufficient preclinical data that will allow us to develop human AM/AMBP-1 as a safe and effective therapy for patients with sepsis, especially those who develop sepsis after trauma or major surgery.
R43DK080512 Qiang (PI) 09/01/09-08/30/11 NIH/NIDDK A Novel Therapeutic Approach for Liver Injury The aim of this project is to demonstrate the feasibility of further development and commercialization of human AM/AMBP-1 as a novel therapeutic approach to reduce mortality after hepatic I/R. Role: Co-PI
DR080669 Wu (PI) 07/01/09-01/31/11 DoD/DRMRP ($245,300) Treatment of TBI and Concomitant Hemorrhage with Ghrelin In this proposal, we will first, determine the short-term effect of ghrelin on brain injury following TBI and uncontrolled hemorrhagic shock and then, determine the long-term effect of ghrelin on brain function following TBI and uncontrolled hemorrhagic shock.
R44HL080748 Wu (PI) 09/10/07-08/31/10 NIH/NHLBI ($1,785,043) A Novel Resuscitation for Hemorrhagic Shock: AM/AMBP-1 This SBIR Phase II proposal is intended to further develop a novel therapeutic approach (i.e., AM/AMBP-1) to save the lives of severely injured trauma victims with hemorrhagic shock.
Postdoctoral Fellowship Wu (Awardee) 07/01/03-06/30/05 (#0325802T) American Heart Association The Role of Ghrelin Receptor in Cardiovascular Responses in Sepsis Three specific aims were proposed. Aim 1: To further confirm that the enhanced cardiovascular responsive-ness to ghrelin is responsible for producing the hyperdynamic response in early sepsis. Aim 2: To determine the mechanism responsible for the upregulated expression of vascular GHS-R in early sepsis. Aim 3: To determine whether administration of ghrelin maintains the cardiovascular stability in late sepsis.
NO. 30000161 Wu (PI) 01/01/01-12/31/03 National Natural Science Foundation of China Mechanisms of Gene Transcription in Endothelial Cells during MODS The purpose of this grant was to investigate the inflammatory signaling pathways in endothelial cells during multiple organ dysfunction syndrome.
|
